154 related articles for article (PubMed ID: 36519123)
1. Intravenous Cyclophosphamide Therapy for Anti-IFN-γ Autoantibody-Associated
Zeng W; Tang M; Yang M; Fang G; Tang S; Zhang J
Open Forum Infect Dis; 2022 Dec; 9(12):ofac612. PubMed ID: 36519123
[TBL] [Abstract][Full Text] [Related]
2. Th1 cell immune response in
Qiu Y; Li Z-T; Zeng W; Yang J-L; Tang M-X; Wang Y; Wang H-R; Li Y; Zhan Y-Q; Li S-Q; Zhang J-Q; Ye F
Microbiol Spectr; 2024 May; 12(5):e0364623. PubMed ID: 38497717
[TBL] [Abstract][Full Text] [Related]
3. Intravenous Cyclophosphamide Therapy for Anti-IFN-Gamma Autoantibody-Associated
Chetchotisakd P; Anunnatsiri S; Nanagara R; Nithichanon A; Lertmemongkolchai G
J Immunol Res; 2018; 2018():6473629. PubMed ID: 30687765
[TBL] [Abstract][Full Text] [Related]
4. Clinical findings of Talaromyces marneffei infection among patients with anti-interferon-γ immunodeficiency: a prospective cohort study.
Chen ZM; Li ZT; Li SQ; Guan WJ; Qiu Y; Lei ZY; Zhan YQ; Zhou H; Lin S; Wang X; Li Z; Yang F; Zeng W; Lin Y; Liu J; Zhang JQ; Ye F
BMC Infect Dis; 2021 Jun; 21(1):587. PubMed ID: 34144700
[TBL] [Abstract][Full Text] [Related]
5. Talaromyces marneffei and nontuberculous mycobacteria co-infection in HIV-negative patients.
Qiu Y; Huang J; Li Y; Zeng W; Pan M; Cen J; Zhang H; Sun X; Qu D; Zhang J
Sci Rep; 2021 Aug; 11(1):16177. PubMed ID: 34376749
[TBL] [Abstract][Full Text] [Related]
6. Coinfection by
Jin W; Liu J; Chen K; Shen L; Zhou Y; Wang L
J Int Med Res; 2021 Jan; 49(1):300060520976471. PubMed ID: 33435770
[TBL] [Abstract][Full Text] [Related]
7.
Lin F; Yang Z; Qiu Y; Zeng W; Liu G; Zhang J
Infect Drug Resist; 2021; 14():5005-5013. PubMed ID: 34866920
[TBL] [Abstract][Full Text] [Related]
8. Talaromyces marneffei and Mycobacterium tuberculosis co-infection in a patient with high titer anti-interferon-γ autoantibodies: a case report.
Qiu Y; Pan M; Yang Z; Zeng W; Zhang H; Li Z; Zhang J
BMC Infect Dis; 2022 Jan; 22(1):98. PubMed ID: 35090402
[TBL] [Abstract][Full Text] [Related]
9. Pathogen spectrum and immunotherapy in patients with anti-IFN-γ autoantibodies: A multicenter retrospective study and systematic review.
Qiu Y; Fang G; Ye F; Zeng W; Tang M; Wei X; Yang J; Li Z; Zhang J
Front Immunol; 2022; 13():1051673. PubMed ID: 36569827
[TBL] [Abstract][Full Text] [Related]
10. Clinical findings and predictive factors for positive anti-interferon-γ autoantibodies in patients suffering from a non-tuberculosis mycobacteria or Talaromyces marneffei infection: a multicenter prospective cohort study.
Qiu Y; Tang M; Zeng W; Feng X; Pan M; Li W; Zhang J
Sci Rep; 2022 May; 12(1):9069. PubMed ID: 35641599
[TBL] [Abstract][Full Text] [Related]
11. Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections.
Guo J; Ning XQ; Ding JY; Zheng YQ; Shi NN; Wu FY; Lin YK; Shih HP; Ting HT; Liang G; Lu XC; Kong JL; Wang K; Lu YB; Fu YJ; Hu R; Li TM; Pan KS; Li XY; Huang CY; Lo YF; Chang IY; Yeh CF; Tu KH; Tsai YH; Ku CL; Cao CW
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32880631
[TBL] [Abstract][Full Text] [Related]
12. Talaromyces marneffei infection relapse presenting as osteolytic destruction followed by suspected nontuberculous mycobacterium infection during 6 years of follow-up: A case update.
Liang X; Si L; Li Y; Zhang J; Deng J; Bai J; Li M; He Z
Int J Infect Dis; 2020 Apr; 93():208-210. PubMed ID: 32105768
[TBL] [Abstract][Full Text] [Related]
13. Anti-Interferon-γ Autoantibodies Impair T-Lymphocyte Responses in Patients with
Chen ZM; Yang XY; Li ZT; Guan WJ; Qiu Y; Li SQ; Zhan YQ; Lei ZY; Liu J; Zhang JQ; Wang ZF; Ye F
Infect Drug Resist; 2022; 15():3381-3393. PubMed ID: 35789796
[TBL] [Abstract][Full Text] [Related]
14. Prospective Pilot Study of Cyclophosphamide as an Adjunct Treatment in Patients With Adult-Onset Immunodeficiency Associated With Anti-interferon-γ Autoantibodies.
Laisuan W; Pisitkun P; Ngamjanyaporn P; Suangtamai T; Rotjanapan P
Open Forum Infect Dis; 2020 Feb; 7(2):ofaa035. PubMed ID: 32099846
[TBL] [Abstract][Full Text] [Related]
15. Disseminated Talaromyces marneffei and Mycobacterium abscessus in a Patient With Anti-Interferon-γ Autoantibodies.
Pruetpongpun N; Khawcharoenporn T; Damronglerd P; Suthiwartnarueput W; Apisarnthanarak A; Rujanavej S; Suwantarat N
Open Forum Infect Dis; 2016 Apr; 3(2):ofw093. PubMed ID: 27419165
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Contreras G; Tozman E; Nahar N; Metz D
Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
[TBL] [Abstract][Full Text] [Related]
17. A case report of Talaromyces marneffei Oro-pharyngo-laryngitis: a rare manifestation of Talaromycosis.
Wongkamhla T; Chongtrakool P; Jitmuang A
BMC Infect Dis; 2019 Dec; 19(1):1034. PubMed ID: 31805893
[TBL] [Abstract][Full Text] [Related]
18. Talaromyces marneffei infection with IFNGR1 gene mutation in a patient with negative Anti-Interferon-γ autoantibodies.
Li S; Cao X; Guo Z; Wang J; Tong J; Zhang Z
An Bras Dermatol; 2024; 99(2):233-237. PubMed ID: 37926601
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and Outcomes of Anti-interferon Gamma Antibody-Associated Adult Onset Immunodeficiency.
Zhang B; Fan J; Huang C; Fan H; Chen J; Huang X; Zeng X
J Clin Immunol; 2023 Oct; 43(7):1660-1670. PubMed ID: 37365453
[TBL] [Abstract][Full Text] [Related]
20. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
Arends S; Berden JH; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M;
Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
